Lv217
170 积分 2024-02-26 加入
High-resolution mass spectrometry-based approach for the identification and profiling of the metabolites of taletrectinib formed in liver microsomes
1小时前
已完结
Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1þ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies
4天前
已完结
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
4天前
已完结
Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1)
4天前
已完结
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data
4天前
已完结
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
15天前
已完结
Inhibition of KAT6A Enhances Immunotherapy Efficacy in Colorectal Cancer by Activating Interferon Response
15天前
已完结
HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer
15天前
已完结
Computational de novo design of antibodies binding to a peptide with high affinity
28天前
已完结
AI-based IsAb2.0 for antibody design
28天前
已完结
皖公网安备34019202002308
